Fibrobiologics, INC Form 4 insider transactions

CEO Pete O'Heeron was granted options to purchase 92,410 shares of FibroBiologics common stock.

Chief Scientific Officer Hamid Khoja was granted options to purchase 61,607 shares of FibroBiologics common stock.

FibroBiologics CFO Jason Davis was granted options to purchase 61,607 shares of common stock at an exercise price of $1.38.

General Counsel Ruben A. Garcia was granted options to purchase 61,607 shares of FibroBiologics common stock.

FibroBiologics' Chief Scientific Officer, Hamid Khoja, acquired 30,000 shares of common stock at $0.38 per share.

FibroBiologics CEO Pete O'Heeron acquired over 51,000 shares of company common stock in early March 2026, increasing his direct beneficial ownership.

FibroBiologics, Inc.'s Chief Financial Officer, Jason Davis, acquired 70,000 shares of common stock at a weighted average price of $0.4139 per share.

FibroBiologics' General Counsel, Ruben A. Garcia, reported the purchase of 40,000 shares of common stock at a weighted average price of $0.3264.

FibroBiologics General Counsel Ruben A. Garcia purchased 140,000 shares of common stock at a weighted average price of $0.34 on December 11, 2025.

Victoria Ninon Olivia Niklas, a Director at FibroBiologics, Inc., acquired 22,000 stock options with an exercise price of $0.8725 on June 12, 2025.

FibroBiologics, Inc. (FBLG) Director and 10% Owner Matthew Link has been granted 22,000 stock options with an exercise price of $0.8725 per share.

FibroBiologics, Inc. Director Robert E. Hoffman was granted 22,000 stock options with an exercise price of $0.8725, vesting upon the earlier of the first anniversary of the grant date or the next annual meeting.

FibroBiologics, Inc. Director Stacy Ann Coen was granted 22,000 stock options with an exercise price of $0.8725, vesting upon the earlier of the first anniversary of the grant date or the next annual meeting.

FibroBiologics, Inc. Director Richard C. Cilento Jr. was granted 22,000 stock options with an exercise price of $0.8725, vesting upon the earlier of the first anniversary of the grant date or the next annual meeting.

FibroBiologics, Inc. Chief Financial Officer Jason Davis was granted an option to purchase 450,000 shares of common stock at an exercise price of $0.9448 per share, vesting over approximately four years.

FibroBiologics, Inc.'s Chief Scientific Officer, Hamid Khoja, has acquired 20,000 shares of common stock, increasing his direct beneficial ownership.

FibroBiologics CEO Pete O'Heeron was granted options to purchase 453,000 shares of common stock on March 26, 2025.

Ruben A. Garcia, General Counsel of FibroBiologics, Inc., was granted stock options to purchase 189,000 shares of common stock on March 26, 2025.

Hamid Khoja, Chief Scientific Officer of FibroBiologics, Inc., was granted options to purchase 189,000 shares of common stock on March 26, 2025.

FibroBiologics CEO Pete O'Heeron was granted options to purchase 406,339 shares of common stock on December 27, 2024.

FibroBiologics' Chief Scientific Officer, Hamid Khoja, was granted stock options for 176,200 shares on December 27, 2024.

FibroBiologics' General Counsel, Ruben A. Garcia, was granted stock options for 176,200 shares of common stock on December 27, 2024.

FibroBiologics CEO, Pete O'Heeron, acquired 100,000 shares of common stock on December 9, 2024.

FibroBiologics CEO Pete O'Heeron reported a disposition of 50,000 common shares on December 3, 2024, resulting in a total beneficial ownership of 6,006,647 shares.

Director Niklas Victoria Ninon Olivia reports acquisition of stock options in FibroBiologics, Inc.

Director Matthew Link of FibroBiologics, Inc. reports acquisition of stock options.

Robert E. Hoffman, a director at FibroBiologics, Inc., acquired 5,000 stock options on August 27, 2024, at an exercise price of $1.73.

Director Stacy Ann Coen acquired 5,000 stock options in FibroBiologics, Inc. on August 27, 2024, at an exercise price of $1.73.

Richard C. Cilento Jr., a director of FibroBiologics, Inc., acquired 5,000 stock options on August 27, 2024.

FibroBiologics CEO Pete O'Heeron acquired 8,500 shares of the company's common stock at an average price of $1.914 on August 12, 2024.